NICE Backs Eylea After Securing Patient Access Scheme From Bayer
This article was originally published in The Pink Sheet Daily
Blockbuster seller Eylea gains momentum with the U.K. health technology assessment agency its use for treating diabetic macular edema after the injectable’s local vendor Bayer grants the National Health Service an undisclosed price discount.
You may also be interested in...
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.